Welcome to our dedicated page for Volitionrx SEC filings (Ticker: VNRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
VolitionRx’s SEC filings are packed with pages of nucleosomics data, clinical-trial updates and financing details that can overwhelm even seasoned analysts. Missing a single Form 8-K about a new licensing deal or overlooking insider buying in a Form 4 could distort your view of this diagnostics innovator. Stock Titan’s AI turns those dense disclosures into clear takeaways, so you can focus on the science and the numbers that move VNRX’s valuation.
Our platform ingests every submission to EDGAR the instant it drops and produces plain-English highlights, red-flag alerts and side-by-side comparisons. Whether you’re searching for “VolitionRx quarterly earnings report 10-Q filing” or need “VolitionRx insider trading Form 4 transactions” before market open, we have you covered. Key documents are mapped to the insights they contain:
- 10-K / annual report — cash-burn trends, patent status, and pipeline milestones in one “VolitionRx annual report 10-K simplified” summary.
- 10-Q / quarterly earnings — segment spending, licensing revenue and trial enrollment metrics with concise “VolitionRx earnings report filing analysis”.
- 8-K — real-time alerts on material events; think “VolitionRx 8-K material events explained” minutes after filing.
- Form 4 — “VolitionRx Form 4 insider transactions real-time” so you can track executive stock moves the moment they file.
- DEF 14A proxy — drill into “VolitionRx proxy statement executive compensation” without digging through appendices.
Use Stock Titan’s AI-powered summaries, red-flag detectors and historical sidebars to understand R&D spend, dilution risk and partnership economics—“understanding VolitionRx SEC documents with AI” has never been easier. Schedule custom alerts, export tables for models and compare “VolitionRx executive stock transactions Form 4” against peer trends, all from one screen.
Terig Hughes, Chief Financial Officer and Director of VolitionRX Limited (VNRX), was awarded 26,143 restricted stock units (RSUs) on 08/15/2025 in lieu of cash compensation. The Form 4 shows the RSUs were granted at a price of $0 and the reporting person beneficially owned 533,770 shares following the award. The RSUs are earned in six approximately equal monthly installments beginning 09/01/2025 and, once earned, remain subject to additional time-based vesting in two installments of 13,072 units on 11/01/2025 and 13,071 units on 02/01/2026. The award is subject to continued service through each earning and vesting date and will settle into a like number of common shares upon vesting.
VolitionRX Ltd. (VNRX) reporting person Ann-Louise Batchelor was awarded 27,400 restricted stock units (RSUs) on 08/15/2025 under the companys 2015 Stock Incentive Plan in lieu of cash compensation. The RSUs are earned in six approximately equal monthly installments beginning 09/01/2025 and, once earned, remain subject to additional time-based vesting in two equal installments of 13,700 units on 11/01/2025 and 02/01/2026. Upon vesting and settlement each RSU converts into one share of common stock. The filing reports 159,886 shares beneficially owned directly after the transaction and 29,406 shares held indirectly by spouse. The award is conditioned on continued service through the applicable earning and vesting dates.
Rodney Gerard Rootsaert, a director and officer (Secretary) of VolitionRx Limited (VNRX), reported an award of 15,223 restricted stock units (RSUs) on 08/15/2025 issued in lieu of cash compensation. The RSUs were granted at $0 price and will be earned in six approximately equal monthly installments beginning 09/01/2025. Once earned, the RSUs remain subject to additional time-based vesting in two installments of 7,612 and 7,611 on 11/01/2025 and 02/01/2026, respectively.
The filing shows Mr. Rootsaert directly beneficially owns 149,233 common shares following the award and has indirect beneficial ownership of 1,007,718 shares held by Concord International, Inc., where he is a controlling director with shared voting and dispositive power.
VolitionRX Limited insider filing shows an award of restricted stock units and a separate disposal of shares by a reporting person. The reporting person, Salvatore Thomas Butera, was awarded 33,991 restricted stock units (RSUs) on 08/15/2025 in lieu of cash compensation; the RSUs are earned in six approximately equal monthly installments beginning 09/01/2025 and, once earned, remain subject to additional time-based vesting in two installments of 16,996 and 16,995 units on 11/01/2025 and 02/01/2026, respectively. The RSUs convert to common shares upon vesting and settlement. The filing also records a disposal of 99,350 shares of common stock that are jointly owned by the reporting person and his spouse. The reporting person is CEO - Volition Veterinary and a director of VolitionRX (VNRX).
VolitionRx Ltd. insider Andrew Retter, Chief Medical Officer and director, was awarded 19,524 restricted stock units (RSUs) on 08/15/2025 in lieu of cash compensation. The RSUs are scheduled to be earned in six approximately equal monthly installments beginning 09/01/2025 and, once earned, will remain subject to additional time-based vesting in two equal installments of 9,762 units on 11/01/2025 and 02/01/2026. The RSUs are contingent on the reporting persons continued service during the earning and vesting periods. After the award, the reporting person beneficially owns 151,156 shares of common stock as reported on the Form 4.
VolitionRX Limited insider filing (Form 4) reports that director and officer Nicholas Plummer was awarded 24,031 restricted stock units (RSUs) on 08/15/2025 in lieu of cash compensation. The RSUs are granted under the Issuer's 2015 Stock Incentive Plan, have a reported price of $0, and will be earned in six approximately equal monthly installments beginning 09/01/2025. Once earned, the awards remain subject to additional time-based vesting in two installments of 12,016 units on 11/01/2025 and 12,015 units on 02/01/2026. The filing shows 207,877 shares beneficially owned by the reporting person following the transaction.
VolitionRX Limited director Ethel Rubin was awarded 17,424 restricted stock units (RSUs) on August 15, 2025 under the companys 2015 Stock Incentive Plan in lieu of cash compensation. The RSUs are earned in six approximately equal monthly installments beginning August 1, 2025, and once earned they remain subject to further time-based vesting in two equal installments of 8,712 units on each of November 1, 2025 and February 1, 2026. Vesting and settlement will deliver common stock equal to the number of RSUs earned and vested, and continued service is generally required through each applicable earning and vesting date. Following the award, the reporting person beneficially owns 62,948 shares. The Form 4 was signed by Ethel Rubin on August 19, 2025.
VolitionRx Limited (VNRX) director Kim Nguyen was awarded 17,424 restricted stock units (RSUs) on August 15, 2025 in lieu of cash compensation under the companys 2015 Stock Incentive Plan. The RSUs are earned in six approximately equal monthly installments beginning August 1, 2025, and once earned they remain subject to additional time-based vesting in two equal installments of 8,712 units on November 1, 2025 and February 1, 2026. Upon vesting and settlement, each RSU converts to one share of common stock. After the award, the reporting person beneficially owned 115,816 shares directly and 30,556 shares indirectly (by spouse).
VolitionRX Limited director and CEO - Singapore Jasmine Kway was granted 12,507 restricted stock units (RSUs) on 08/15/2025 in lieu of cash compensation. The RSUs are earned in six approximately equal monthly installments beginning 09/01/2025 and, once earned, remain subject to additional time-based vesting in two installments of 6,254 RSUs on 11/01/2025 and 6,253 RSUs on 02/01/2026. Upon vesting and settlement, each vested RSU converts into one share of common stock. Following the award, the reporting person beneficially owns 203,614 shares, with 10,400 shares held indirectly by spouse.
Gael Forterre, Chief Commercial Officer of VolitionRx Limited (VNRX), was awarded 9,727 restricted stock units (RSUs) on August 15, 2025 in lieu of cash compensation. The RSUs are payable in shares upon settlement and will be earned in six approximately equal monthly installments beginning September 1, 2025. Once earned, the RSUs remain subject to additional time-based vesting in two installments of 4,864 units on November 1, 2025 and 4,863 units on February 1, 2026, and require continued service for each applicable earning and vesting date.
Following the award, Mr. Forterre directly beneficially owns 166,427 shares and indirectly holds 5,000 shares through his spouse and 32,500 shares managed by Armorica Partners, LLC, of which he is the managing director and sole shareholder; he disclaims beneficial ownership except for pecuniary interest.
FAQ
What is the current stock price of Volitionrx (VNRX)?
What is the market cap of Volitionrx (VNRX)?
